Key facts: AstraZeneca will invest $50 billion in U.S. manufacturing by 2030, including a major facility in Virginia and expansions in several states. The company is also managing inventory for tariff impacts.
Thời gian đọc: dưới 1 phút
- AstraZeneca will invest $50 billion in U.S. manufacturing by 2030, including a major facility in Virginia and expansions in several states. The company is also managing inventory for tariff impacts.1
- AstraZeneca is involved in a patent lawsuit in Delaware, accused by Factor Bioscience of infringing on three gene-editing patents related to cancer treatments, seeking monetary damages.2
- AstraZeneca will sell its diabetes drug Farxiga for $182 and asthma drug Airsupra for $249 to cash-paying U.S. patients, offering discounts up to 70% starting October 1.34